Prelude Capital Management, LLC Cytek Biosciences, Inc. Transaction History
Prelude Capital Management, LLC
- $1.23 Billion
- Q1 2025
A detailed history of Prelude Capital Management, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 19,200 shares of CTKB stock, worth $66,816. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,200
Previous 28,880
33.52%
Holding current value
$66,816
Previous $187,000
59.36%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding CTKB
# of Institutions
160Shares Held
73.8MCall Options Held
600Put Options Held
4.9K-
Black Rock Inc. New York, NY17.1MShares$59.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.62MShares$33.5 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.46MShares$26 Million0.93% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$23.2 Million0.82% of portfolio
-
State Street Corp Boston, MA4.38MShares$15.2 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $469M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...